Nachrichten zur Vanda Pharmaceuticals Aktie

Quartalszahlen im Zeichen von Investitionen Vanda Pharmaceuticals (VNDA) blickt im ersten Quartal 2026 auf eine Phase der strategischen Marktexpansion zurück,…

…

Vanda Pharmaceuticals stock surges after the FDA approves its new Bipolar I drug…

…

Vanda (VNDA) delivered earnings and revenue surprises of +78.85% and -2.78%, respectively, for the quarter ended December 2025. Do the…

…

Vanda Pharmaceuticals (VNDA) hat sich in der biopharmazeutischen Branche als Spezialist für Erkrankungen des zentralen Nervensystems und seltene Krankheiten etabliert.…

US FDA approves Vanda Pharmaceuticals’ motion sickness drug…

Vanda Pharmaceuticals stock rises after FDA lifts partial clinical hold…

…

Vanda (VNDA) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2024. Do the…

…

…

Vanda Pharmaceuticals rejects Cycle Pharmas second takeover offer…

Cycle Pharmaceuticals Ltd. is still interested in acquiring Vanda Pharmaceuticals Inc. after one of Vanda’s drugs failed to receive regulatory…

…

Court advances Vanda Pharmaceuticals patent case…

…

…

The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…

…

…

U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents…

…

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Dublin, March 04, 2024 (GLOBE NEWSWIRE) -- The "Dyspepsia - Pipeline Insight, 2024" report has been added to…